AKIGAI

About AKIGAI

AKIGAI will disrupt the field of neuropathic pain (NP) by 2027.
With 4 layers to protect our EGFR inhibitor (EGFR-I) in the market, AKIGAI will reposition EGFR-Is, well known cancer drugs, for the treatment of NP.
Founders are oncologists, who serendipitously observed dramatic NP relief by EGFR-Is in the clinics. We have rarely witnessed such dramatic and meaningful drug effects as by ...

  • NO
  • 2024
    On CPHI since
  • 1 - 24
    Employees
Company types
Other
Start-up
Primary activities
Pharmaceutical Company (generic finished products)
Contact info

AKIGAI Resources (1)